Moreover, the same group later described how the inhibition of DYRK2 activity mediated by curcumin and LDN192960 reduces cell proliferation and induces cell death, thus compromising triple-negative breast cancer (TNBC) [13] and multiple myeloma (MM) growth [14]. Here, DYRK2 is linked to triple-negative breast carcinoma.